Afatinib and palbociclib for advanced esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two targeted drugs (afatinib and palbociclib) for people with advanced esophageal squamous cell carcinoma that has grown after previous treatment. It is designed for those whose cancer cells have too much of a protein called EGFR.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced esophageal squamous cell carcinoma that cannot be removed by surgery and has spread or come back after treatment.
- Your tumor cells have a lot of EGFR (a protein that helps cancer grow), as shown by a lab test.
- Your cancer has gotten worse after at least one prior treatment.
- You are in generally good health (able to do daily activities with little or no help).
- Your heart, liver, and kidney function are adequate based on blood tests and an ultrasound of your heart.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized treatment approach for advanced esophageal cancer that has stopped responding to immunotherapy. It aims to find better options for people whose cancer has progressed after standard treatments.
This trial tests a combination of three drugs (adebrelimab, apatinib, and a chemotherapy pill) for people with advanced esophageal cancer whose previous immunotherapy treatment stopped working. The goal is to see if this new combination can help the immune system fight the cancer again.
This trial tests a combination of three drugs—becotatug vedotin, tislelizumab, and low-dose lenvatinib—for people with advanced esophageal cancer that has progressed after standard treatment. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests a new combination of drugs for people with esophageal squamous cell carcinoma that is advanced or has spread. The goal is to see if the combination can help shrink tumors or slow the disease.
This trial tests a new combination of two drugs, anlotinib and benmelstobart, for people with advanced esophageal squamous cell carcinoma that has not been treated before or has come back after more than six months. The goal is to see if this combination can help control the cancer and improve outcomes.
This trial tests a new combination of treatments for people with advanced esophageal cancer that can't be removed by surgery. It uses a targeted therapy called surufatinib along with chemo-immunotherapy and radiation to see if it can shrink the tumor before further treatment.
Hear when a new Esophagus Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.